
Danish biotech company Zealand Pharma and its collaborative partner, German pharmaceutical company Boehringer Ingelheim, are initiating stage II trials with the drug candidate BI 456906.
They will take the shape of a once-weekly treatment for obesity on the one hand, and of a treatment for the fatty liver disease NASH on the other, according to a press statement from Zealand Pharma on Tuesday afternoon.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app